Real-World data shows lanadelumab cuts HAE attacks over three years
NCT ID NCT04130191
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study followed 140 people with hereditary angioedema (HAE) who were already taking lanadelumab. Researchers compared the number of swelling attacks during treatment to the number before starting the drug. Participants reported their symptoms via a smartphone app and during clinic visits for up to three years. The goal was to see how well lanadelumab works in everyday life, not just in controlled trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lanadelumab
What this could lead to
If successful, this study could confirm that lanadelumab effectively reduces HAE attacks in everyday use, supporting its long-term role in managing the condition.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient selection or reporting bias. It does not test new treatments or cures.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco
Milan, 20157, Italy
-
Al-Rashed Allergy Center
Kuwait City, 90806, Kuwait
-
Azienda Ospedale Università Padova
Padova, 35128, Italy
-
Azienda Ospedaliera Universitaria Federico II
Naples, Campania, 80131, Italy
-
Bnai Zion Medical Center
Haifa, 31048, Israel
-
Charité - Universitätsmedizin Berlin
Berlin, 10117, Germany
-
Hospital Universitario Vall d'Hebron - PPDS
Barcelona, 08035, Spain
-
Hospital Universitario de Bellvitge
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Hämophilie Zentrum Rhein Main GmbH
Mörfelden-Walldorf, 64546, Germany
-
Klinikum der Johann-Wolfgang Goethe-Universitat
Frankfurt am Main, Hesse, 60590, Germany
-
Klinikum rechts der Isar der Technischen Universität München
München, 81675, Germany
-
Luzerner Kantonsspital LUKS
Lucerne, 6000, Switzerland
-
Medical University of Vienna
Vienna, 1090, Austria
-
Sheba Medical Center - PPDS
Ramat Gan, 52621, Israel
-
Universitatsklinikum Dusseldorf
Düsseldorf, 40225, Germany
-
Universitatsklinikum Schleswig-Holstein
Lübeck, 23538, Germany
-
Universitätsklinikum Münster
Münster, 48149, Germany
-
Universitätsklinikum Ulm
Ulm, 89075, Germany
-
Universitätsspital Basel
Basel, 4031, Switzerland